Astonea Labs Limited’s Board of Directors approved the appointment of Chander Shekhar as internal auditor for FY27 on September 9, 2026. The meeting also covered cost audit reports, a new subsidiary, and overseas investment.

The Board considered and took on record the Cost Audit Report for FY26 received from Mukesh Kumar Gupta of M/s. Balwinder & Associates. The report contained no adverse remarks or qualifications.

Internal Auditor Appointment

Chander Shekhar, a Chartered Accountant with Membership No. 506340 and Firm Registration No. 020828N, was appointed pursuant to Section 138 of the Companies Act, 2013. He is not related to any director or key managerial personnel.

Subsidiary Incorporation

The Board approved the incorporation of Longevity Science Private Limited as a wholly owned subsidiary, holding at least 51% voting power. A name correction application is pending for an erroneous submission to the Registrar of Companies.

Overseas Direct Investment

Astonea Labs approved an initial capital investment of up to $10,000 in Astonea LLC, its wholly owned US subsidiary in Wyoming. The investment complies with FEMA and ODI regulations.

Agreement Termination

The Board confirmed the immediate termination of material supply and distribution agreements with Astonea One Private Limited, superseding a previous deferral decision.

Astonea Labs Limited shareholders unanimously approved all agenda items at its ninth annual general meeting held on August 21, 2026. The key resolution included the re-appointment of Ms. Pooja Singh as a director.

Ms. Singh, who holds a Bachelor of Pharmacy degree and possesses over eight years of experience in the pharmaceutical industry, was liable to retire by rotation. She currently heads the Drug Regulatory Affairs Department and serves on the CSR Committee. She has no shareholding in the company and is not related to any other director or key managerial personnel.

The meeting took place at the Mercure Hotel in Chandigarh, marking the first such gathering since the company’s securities were listed. Six members attended the physical session, satisfying quorum requirements under Section 103 of the Companies Act, 2013.

Financial Results Adopted

Shareholders adopted the audited standalone and consolidated financial statements for FY26. The company reported revenue of approximately ₹148 crore and a profit after tax (PAT) of approximately ₹4.51 crore for the financial year ended March 31, 2026.

Voting Participation Breakdown

The total outstanding shares stood at 10,511,000. Of these, 7,839,000 votes were polled through the National Securities Depository Limited (NSDL) e-voting facility. No votes were cast via ballot paper during the physical meeting.

Promoters held 7,599,970 shares and voted nearly all their holdings (99.93%). Public non-institutional investors participated at a lower rate of 9.91%, while institutional public shareholders did not vote.

Other Resolutions Approved

All resolutions passed with unanimous support from the voting members. Additional approvals included:

• Ratification of remuneration for M/s. Balwinder & Associates as Cost Auditor for FY27.
• Alteration in the Object Clause of the Memorandum of Association.
• Approval for incorporation and investment in subsidiary companies in India.

Governance and Compliance

Mr. Sahil Malhotra of SV & Associates served as the scrutinizer for the voting process. He confirmed that the e-voting facility was open from August 18 to August 20, 2026. The consolidated voting results were submitted to the BSE within two working days as per SEBI Listing Regulations.

Ashish Gulati, Chairman, presided over the session. He highlighted the company’s focus on strengthening pharmaceutical and allied operations while maintaining regulatory compliance and corporate governance standards.